-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C60FFHMD1pUTO2u6wEEj/YTIM1R+DsXtIYH5G07s3jh7y7QjYAmepVgD+uLBezz9 MjNAn0goasujkTukrs3GSg== 0001144204-09-027551.txt : 20090515 0001144204-09-027551.hdr.sgml : 20090515 20090515162332 ACCESSION NUMBER: 0001144204-09-027551 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090331 FILED AS OF DATE: 20090515 DATE AS OF CHANGE: 20090515 EFFECTIVENESS DATE: 20090515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 09833440 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v149187_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2009 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. May 15, 2009 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 74 ----------- Form 13F Information Table Entry Value: 995,887 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 3-31-2009
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 2,789 2,935,420 SH SOLE 2,935,420 Acorda Therapeutics COM 00484M106 23,853 1,204,083 SH SOLE 1,204,083 Adolor Corp. COM 00724X102 478 234,515 SH SOLE 234,515 Allergan COM 018490102 1,232 25,800 SH SOLE 25,800 Allos Therapeutics Inc. COM 019777101 49,447 8,001,130 SH SOLE 8,001,130 Alsius Corp. COM 021211107 16 62,872 SH SOLE 62,872 Altus Pharmaceuticals Inc. COM 02216N105 16 70,494 SH SOLE 70,494 Amicus Therapeutics COM 03152W109 11,887 1,302,004 SH SOLE 1,302,004 Anadys Pharmaceuticals Inc. COM 03252Q408 4,403 648,486 SH SOLE 648,486 AP Pharma COM 00202J203 1,558 2,884,546 SH SOLE 2,884,546 Aradigm Corp. COM 038505301 14 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 52,958 5,146,589 SH SOLE 5,146,589 Ariad COM 04033A100 2,339 1,965,713 SH SOLE 1,965,713 Autoimmune Inc. COM 052776101 13 13,050 SH SOLE 13,050 Auxilium COM 05334D107 113,960 4,111,128 SH SOLE 4,111,128 Biocryst Pharmaceuticals Inc. COM 09058V103 13,974 6,380,689 SH SOLE 6,380,689 Biomarin COM 09061G101 2,074 167,946 SH SOLE 167,946 Cadence Pharmaceuticals COM 12738T100 5,981 637,662 SH SOLE 637,662 Celgene COM 151020104 26,996 608,019 SH SOLE 608,019 Cepheid COM 15670R107 415 60,100 SH SOLE 60,100 Chelsea Therapeutics COM 163428105 1,738 1,136,263 SH SOLE 1,136,263 Cornerstone BioPharma COM 22674T105 461 112,337 SH SOLE 112,337 Curagen COM 23126R101 350 388,613 SH SOLE 388,613 Cyclacel Pharmaceuticals COM 23254L108 31 85,811 SH SOLE 85,811 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 157 92,311 SH SOLE 92,311 Cytokinetics Inc. COM 23282W100 2,207 1,298,432 SH SOLE 1,298,432 Depomed COM 249908104 432 183,145 SH SOLE 183,145 Genomic Health Inc. COM 37244C101 126,785 5,200,387 SH SOLE 5,200,387 Halozyme Therapeutics Inc. COM 40637H109 10,999 2,014,512 SH SOLE 2,014,512 Icagen Inc. COM 45104P104 19 46,373 SH SOLE 46,373 Idera Pharmaceuticals Inc. COM 45168K108 3,328 514,328 SH SOLE 514,328 Immunogen Inc. COM 45253H101 3,580 504,234 SH SOLE 504,234 Immunomedics, Inc. COM 452907108 46 47,704 SH SOLE 47,704 Incyte Corp. COM 45337C102 26,146 11,173,417 SH SOLE 11,173,417 Infinity Pharmaceuticals Inc. COM 45665G303 704 85,632 SH SOLE 85,632 Inhibitex Inc. COM 45719T103 156 620,904 SH SOLE 620,904 Insmed COM 457669208 14 13,699 SH SOLE 13,699 Inspire COM 457733103 13,803 3,399,761 SH SOLE 3,399,761 Intermune Inc. COM 45884X103 30,239 1,839,329 SH SOLE 1,839,329 Inverness Medical COM 46126P106 33,894 1,272,786 SH SOLE 1,272,786 Medarex COM 583916101 1,510 294,289 SH SOLE 294,289 Metabasis Therapeutics Inc. COM 59101M105 1,595 2,246,759 SH SOLE 2,246,759 Micromet COM 59509C105 11,770 3,724,585 SH SOLE 3,724,585 Myriad Genetics Inc. COM 62855J104 3,736 82,166 SH SOLE 82,166 Neurogen Corp. COM 64124E106 1,886 8,205,406 SH SOLE 8,205,406 Novo-Nordisk COM 670100205 14,185 295,646 SH SOLE 295,646 Onyx Inc. COM 683399109 1,044 36,578 SH SOLE 36,578 Optimer Pharmaceuticals COM 68401H104 5,600 424,251 SH SOLE 424,251 Pharmasset Inc. COM 71715N106 650 66,247 SH SOLE 66,247 Salix Pharmaceuticals, Inc. COM 795435106 36,237 3,814,396 SH SOLE 3,814,396 Seattle Genetics Inc. COM 812578102 127,314 12,912,124 SH SOLE 12,912,124 Senomyx COM 81724Q107 54 34,114 SH SOLE 34,114 Siga Technologies Inc. COM 826917106 2,909 573,832 SH SOLE 573,832 Sucampo CLASS A 864909106 395 64,387 SH SOLE 64,387 Sunesis Pharmaceuticals Inc. COM 867328502 250 1,252,083 SH SOLE 1,252,083 Supergen COM 868059106 600 331,480 SH SOLE 331,480 Symyx Technologies, Inc. COM 87155S108 325 73,127 SH SOLE 73,127 Targacept COM 87611R306 1,139 425,073 SH SOLE 425,073 Threshold Pharma COM 885807107 1,851 1,504,711 SH SOLE 1,504,711 Torreypines Therapeutics COM 89235K105 6 33,546 SH SOLE 33,546 Trimeris Inc. COM 896263100 6,058 3,461,175 SH SOLE 3,461,175 Vanda Pharmaceuticals Inc. COM 921659108 203 225,142 SH SOLE 225,142 Via Pharmaceuticals COM 92554T103 19 102,881 SH SOLE 102,881 Vion Pharm COM 927624AA4 24 43,101 SH SOLE 43,101 Viropharma Inc. COM 928241108 36,931 7,034,346 SH SOLE 7,034,346 Xenoport Inc. COM 98411C100 10,537 544,271 SH SOLE 544,271 Zymogenetics, Inc. COM 98985T109 2,324 582,500 SH SOLE 582,500 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 20,058 23,465,000 PRN SOLE 23,465,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 17,770 32,000,000 PRN SOLE 32,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 29,240 59,071,000 PRN SOLE 59,071,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAF9 19,938 38,250,000 PRN SOLE 38,250,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 26,323 27,313,000 PRN SOLE 27,313,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 9,766 13,158,000 PRN SOLE 13,158,000 Vertex Pharmaceuticals Notes 4.75% 2/15/13 CONV BONDS 92532FAM2 34,148 25,948,000 PRN SOLE 25,948,000
-----END PRIVACY-ENHANCED MESSAGE-----